Publications: 494 in 2026-04. +3.3% share of all MeSH-indexed PubMed records vs the same month last year (490 in 2025-04).
PublicationsPubMed
4942026-04
+3.3% share of all MeSH-indexed PubMed records vs same month last year (490 in 2025-04)provisional · settling
0.45% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 49 in 2026-09. +36.1% vs the same month last year (36 in 2025-09).
Clinical trialsClinicalTrials.gov
492026-09
+36.1% vs same month last year (36 in 2025-09)
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 191 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 191 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
1912026-09
78th percentilerunning high, versus 16-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 709 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 709 is in the 91st percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
7092026-09
91st percentilenear its historical high, versus 16-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 37 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 37 is in the 72nd percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
372026-09
72nd percentilerunning high, versus 16-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 494 is in the 76th percentile, running high, versus 320 months since 2000.
76thpercentile
running high
494/mo · higher than 76% of 320 months since 2000
Clinical trials
Clinical trials: latest count 49 is in the 99th percentile, near its historical high, versus 316 months since 2000.
99thpercentile
near its historical high
49/mo · higher than 99% of 316 months since 2000
NIH grantsprovisional
NIH grants: latest count 191 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
78thpercentile
running high
191/mo · higher than 75% of 16-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 709 is in the 91st percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
91stpercentile
near its historical high
709/mo · higher than 88% of 16-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 37 is in the 72nd percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
72ndpercentile
running high
37/mo · higher than 69% of 16-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 16 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 316 mo; NIH grants 2025 to 2026 · 16 mo; Patents 2025 to 2026 · 16 mo; Preprints 2025 to 2026 · 16 mo.
Publications2000 to 2026 · 320 mopeak 923/mo
Clinical trials2000 to 2026 · 316 mopeak 57/mo
NIH grants2025 to 2026 · 16 mobackfill pendingpeak 243/mo
Patents2025 to 2026 · 16 mobackfill pendingpeak 858/mo
Preprints2025 to 2026 · 16 mobackfill pendingpeak 46/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2025-04..2026-07
3%of works have an industry affiliation
Chinese Academy of Medical Sciences & Peking Union Medical College102
Johns Hopkins University93
Amsterdam University Medical Centers82
Memorial Sloan Kettering Cancer Center80
University of Amsterdam78
Clinical trials
Lead sponsors · 2023-10..2026-09
22%industry-led in 2026-09
Fudan UniversityAcademic/other31
Ruijin HospitalAcademic/other22
Zhejiang UniversityAcademic/other20
Tianjin Medical University Cancer Institute and HospitalAcademic/other19
Changhai HospitalAcademic/other17
NIH grants
Funded institutions · 2025-06..2026-09
1,886awards in window
UNIVERSITY OF TX MD ANDERSON CAN CTRTX · $45.6M · R01/P3067
JOHNS HOPKINS UNIVERSITYMD · $33.9M · R01/P3064
WASHINGTON UNIVERSITYMO · $32M · U54/P5063
SLOAN-KETTERING INST CAN RESEARCHNY · $31M · R01/P5054
UNIVERSITY OF MICHIGAN AT ANN ARBORMI · $22.4M · R01/P5053
Patents
Applicants · 2025-06..2026-09
The Regents of the University of California100
Genentech, Inc.76
Hoffmann-La Roche Inc.75
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM73
2026-09-29biorxivDepartment of Computational and Systems Biology, University of Pittsburgh; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine; Department o
Would you read a monthly digest for Pancreatic Cancer?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Pancreatic Cancer. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Pancreatic Cancer.
How we map "Pancreatic Cancer"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Pancreatic Neoplasms"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10
Author institutions (OpenAlex)
topic T10231; search 'pancreatic cancer'
Clinical trials (ClinicalTrials.gov)
ConditionSearch: pancreatic cancer OR pancreatic ductal adenocarcinoma OR pancreatic neoplasm